Commands

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alpha for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Due to Myelodysplastic Syndrome (MDS) ESA in Native Subjects Who Require Red Blood Cell Transfusions

Contact Persn: James Nasman

Please contact NasmanJ@sutterhealth.org about study Commands

Principal Investigator

Oleg I. Krijanovski, M.D., Ph.D.

Co-Investigator(s)

Uma Suryadevara, MD 

Recruitment Status

Active, Recruiting

Start Date

March 18, 2020